Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

The National Medical Commission (NMC) has raised serious concerns over financial irregularities, inadequate infrastructure, and deficiencies in medical training, at Dr DY Patil Medical College, ...

To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte files with ... journey through MRD and recurrence testing.

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

The Council today gave its final green light to setting up the Reform and Growth Facility for the Republic of Moldova, a new ...

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment Sys ...

Melcor has been a public company since 1968 and trades on the Toronto Stock Exchange (TSX: MRD). For more information ... could affect Melcor and the REIT are included in reports on file with Canadian ...

Of those evaluable for minimal residual disease (MRD) testing, 93.1% (54/58 ... and the other documents that Arcellx may file from time to time with the SEC. These forward-looking statements ...

and in the ongoing Phase 1 study in patients with measurable residual disease (MRD) in AML. Cash, cash equivalents, short- and long-term investments, and interest receivable were $606.9 million as ...